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Human cytomegalovirus (HCMV) is a widely circulating pathogen that causes severe disease in immuno-
compromised patients and infected fetuses. By immortalizing memory B cells from HCMV-immune donors, we
isolated a panel of human monoclonal antibodies that neutralized at extremely low concentrations (90%
inhibitory concentration [IC90] values ranging from 5 to 200 pM) HCMV infection of endothelial, epithelial,
and myeloid cells. With the single exception of an antibody that bound to a conserved epitope in the UL128 gene
product, all other antibodies bound to conformational epitopes that required expression of two or more
proteins of the gH/gL/UL128-131A complex. Antibodies against gB, gH, or gM/gN were also isolated and, albeit
less potent, were able to neutralize infection of both endothelial-epithelial cells and fibroblasts. This study
describes unusually potent neutralizing antibodies against HCMV that might be used for passive immuno-
therapy and identifies, through the use of such antibodies, novel antigenic targets in HCMV for the design of
immunogens capable of eliciting previously unknown neutralizing antibody responses.
Human cytomegalovirus (HCMV) is a member of the her-
pesvirus family which is widely distributed in the human pop-
ulation and can cause severe disease in immunocompromised
patients and upon infection of the fetus. HCMV infection
causes clinical disease in 75% of patients in the first year after
transplantation (58), while primary maternal infection is a ma-
jor cause of congenital birth defects including hearing loss and
mental retardation (5, 33, 45). Because of the danger posed by
this virus, development of an effective vaccine is considered of
highest priority (51).
HCMV infection requires initial interaction with the cell
surface through binding to heparan sulfate proteoglycans (8)
and possibly other surface receptors (12, 23, 64, 65). The virus
displays a broad host cell range (24, 53), being able to infect
several cell types such as endothelial cells, epithelial cells (in-
cluding retinal cells), smooth muscle cells, fibroblasts, leuko-
cytes, and dendritic cells (21, 37, 44, 54). Endothelial cell tro-
pism has been regarded as a potential virulence factor that might
influence the clinical course of infection (16, 55), whereas infec-
tion of leukocytes has been considered a mechanism of viral
spread (17, 43, 44). Extensive propagation of HCMV labora-
tory strains in fibroblasts results in deletions or mutations of
genes in the UL131A-128 locus (1, 18, 21, 36, 62, 63), which are
associated with the loss of the ability to infect endothelial cells,
epithelial cells, and leukocytes (15, 43, 55, 61). Consistent with
this notion, mouse monoclonal antibodies (MAbs) to UL128
or UL130 block infection of epithelial and endothelial cells but
not of fibroblasts (63). Recently, it has been shown that UL128,
UL130, and UL131A assemble with gH and gL to form a
five-protein complex (thereafter designated gH/gL/UL128-
131A) that is an alternative to the previously described gCIII
complex made of gH, gL, and gO (22, 28, 48, 63).
In immunocompetent individuals T-cell and antibody re-
sponses efficiently control HCMV infection and reduce patho-
logical consequences of maternal-fetal transmission (13, 67),
although this is usually not sufficient to eradicate the virus.
Albeit with controversial results, HCMV immunoglobulins
(Igs) have been administered to transplant patients in associ-
ation with immunosuppressive treatments for prophylaxis of
HCMV disease (56, 57), and a recent report suggests that they
may be effective in controlling congenital infection and pre-
venting disease in newborns (32). These products are plasma
derivatives with relatively low potency in vitro (46) and have to
be administered by intravenous infusion at very high doses in
order to deliver sufficient amounts of neutralizing antibodies
(4, 9, 32, 56, 57, 66).
The whole spectrum of antigens targeted by HCMV-neu-
tralizing antibodies remains poorly characterized. Using spe-
cific immunoabsorption to recombinant antigens and neutral-
ization assays using fibroblasts as model target cells, it was
estimated that 40 to 70% of the serum neutralizing activity is
directed against gB (6). Other studies described human neu-
tralizing antibodies specific for gB, gH, or gM/gN viral glyco-
proteins (6, 14, 26, 29, 34, 41, 52, 60). Remarkably, we have
recently shown that human sera exhibit a more-than-100-fold-
higher potency in neutralizing infection of endothelial cells
than infection of fibroblasts (20). Similarly, CMV hyperimmu-
noglobulins have on average 48-fold-higher neutralizing activ-
ities against epithelial cell entry than against fibroblast entry
(10). However, epitopes that are targeted by the antibodies
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that comprise epithelial or endothelial cell-specific neutralizing
activity of human immune sera remain unknown.
In this study we report the isolation of a large panel of
human monoclonal antibodies with extraordinarily high po-
tency in neutralizing HCMV infection of endothelial and epi-
thelial cells and myeloid cells. With the exception of a single
antibody that recognized a conserved epitope of UL128, all
other antibodies recognized conformational epitopes that re-
quired expression of two or more proteins of the gH/gL/
UL128-131A complex.
MATERIALS AND METHODS
Isolation of human monoclonal antibodies and microneutralization assays.
Following written consent, blood samples were collected from a heart transplant
recipient with reactivated infection (donor A) and three pregnant women with
HCMV primary infection (donors B, C, and D) 5 to 12 months after onset of
infection. The study was approved by the Bioethical Committee of the Fonda-
zione IRCCS Policlinico San Matteo, Pavia, Italy. Memory B cells were isolated
from peripheral blood mononuclear cells (PBMC) by positive selection with
CD22 magnetic beads (Miltenyi Biotec), followed by removal of IgA, IgM,
and IgD cells by cell sorting. The resulting IgG memory B cells were immor-
talized with Epstein-Barr virus (EBV) in the presence of R848 according to a
previously described method (59) and plated at 10 cells/well in 384-well plates.
After 2 to 3 weeks, culture supernatants were screened in parallel in microneu-
tralization assays on fibroblasts (MRC-9; European Collection of Animal Cell
Cultures) and retinal epithelial cells (ARPE-19; ATCC). Supernatants were
mixed with an equal volume of HCMV clinical isolate VR1814 (42) and incu-
bated for 2 h at room temperature before addition to target cell monolayers in
96-well plates. After 36 to 72 h, cells were fixed, permeabilized, and stained with
a murine monoclonal anti-pp72 antibody (19) followed by incubation with anti-
mouse antibody conjugated to AF488 (Molecular Probes). Cultures were in-
spected by fluorescence microscopy with automatic acquisition of 9 images/well
on a BD Pathway instrument (BD Biosciences) with AttoVision software. Cells
from positive cultures were cloned by limiting dilution at 0.5 cells/well. Unique-
ness of the antibodies was confirmed by determination of the sequences of the
variable genes. Antibodies were purified from culture supernatants by affinity
chromatography on HiTrap protein A or protein G columns (GE Healthcare)
followed by desalting on a HiTrap desalting column (GE Healthcare) and bioti-
nylation with the EZ-Link NHS-PEO solid-phase biotinylation kit (Pierce).
Potency of antibodies was determined by mixing serial dilutions of the anti-
bodies with a fixed amount of virus, giving 150 to 500 infected cells/field of
analysis. The number of infected cells was plotted against the concentration of
the antibody. Nonlinear regression analysis with Prism 4 GraphPad software was
applied to obtain sigmoidal dose-response curves (variable slope), and inhibitory
concentrations resulting in 50% or 90% inhibition of infection (IC50 or IC90,
respectively) were calculated. Target cells were human fibroblasts (MRC-9),
retinal epithelial cells (ARPE-19), human umbilical vein endothelial cells
(HUVEC; Lonza), monocyte-derived dendritic cells (Mo-DC) (49), and human
bone marrow mesenchymal stromal cells (BM-MSC) (39). In some experiments
clinical isolates VR6952, VR3480B1, and VR4760 (3, 42, 50) were used on
HUVEC.
Cloning and expression of HCMV genes. Intronless, full-length UL128
(HindIII and XbaI), UL130 (HindIII and XbaI), UL131A (HindIII and XbaI), gH
(HindIII and XbaI), gL (HindIII and XbaI), gB (HindIII and XbaI), gM (HindIII
and XbaI, with C-terminal His tag), and gN (HindIII and XbaI, with C-terminal
FLAG tag) were cloned in pcDNA3 vector (Invitrogen) by PCR with Pfu turbo
(Stratagene) on cDNA of VR1814-infected MRC-9 cells, using primers intro-
ducing the desired restriction sites. Constructs were transfected in HEK293T
cells (ATCC) with Fugene HD (Roche). Cells were harvested 24 to 48 h after
transfection and fixed with 2% formaldehyde. Staining was performed with
antibodies diluted in 0.5% saponin in phosphate-buffered saline (PBS) with 1%
fetal bovine serum (FBS), followed by F(ab)2 fragment goat anti-human IgG,
which was Fc fragment specific and conjugated to Cy5 (Jackson Immuno-
Research). Samples were acquired on a FACSCalibur or with an automated BD
FACS Array instrument (BD Biosciences) and analyzed with FlowJo software.
Ectopic expression of antigens was confirmed by intracellular staining with
mouse MAbs anti-UL128 and UL130 (kindly provided by T. Shenk [63]), gH
(clone 5E259; US Biological), gB (clone 2F12; GeneTex), anti-FLAG (Sigma),
or anti-His (Santa Cruz Biotechnology) or by Western blotting on lysates with
rabbit serum anti-UL131A (kindly provided by B. Adler [1]).
UL128 pan-mutant. Amino acid sequences of UL128 from different clinical
isolates (2) were aligned, and a sequence including mutations at all sites de-
scribed was designed (MNSKDLTPFLTTLWLLLDHSRVPRVRAEECCEVIN
VNHPPERCYDFKMCNLFTVALRCPDGEVCYSPEKTAEIRGIVTTMTH
SLTRQVIHNKLTSCNYNPLYLEADGRIRCGKVSDKAQYLLGAAGSVPY
RWINLEYDKITRIVGLDQYLESVKKHKRLDVCRAKMGYMLQ). The
artificial gene encoding this UL128 pan-mutant was synthesized (Genart), sub-
cloned into pcDNA3.1() (Invitrogen), and transfected in HEK293T cells. Cells
expressing UL128 pan-mutant were costained with 15D8 and mouse anti-UL128
(63), followed by F(ab)2 fragment goat anti-human IgG, which was Fc frag-
ment specific and conjugated to Cy5 (Jackson ImmunoResearch), and F(ab)2
fragment goat anti-mouse Ig conjugated to phycoerythrin (PE; Dako).
RESULTS
Isolation of a panel of HCMV-neutralizing human mono-
clonal antibodies. IgG memory B cells were isolated from
PBMC of HCMV-seropositive patients (three pregnant women
with primary HCMV infection and one heart transplant recip-
ient with reactivated HCMV infection) and immortalized with
EBV according to a previously described method (59). In order
to isolate a representative panel of HCMV-neutralizing anti-
bodies, the primary screening was a neutralization assay that
used an HCMV clinical isolate (VR1814) and either human
fibroblasts (MRC-9) or epithelial cells (ARPE-19) as target
cells. Based on potency of neutralization and cell target spec-
ificity, selected cultures were cloned by limiting dilution in
order to isolate B-cell clones secreting neutralizing monoclonal
antibodies.
Twenty-seven independent B-cell clones were isolated and
characterized (Table 1 and Fig. 1). Of these, 10 produced
antibodies that neutralized HCMV infection of fibroblasts as
well as of epithelial cells (group 1 antibodies). These antibod-
ies showed a spectrum of potencies with IC90 values ranging
from 0.1 g/ml to 30 g/ml (0.7 to 200 nM) and were able to
neutralize infection of primary cells such as HUVEC, Mo-DC,
and BM-MSC (Table 2 and data not shown). A second group
of 17 B-cell clones produced antibodies that neutralized infec-
tion of epithelial cells with extraordinarily high potency (group
2 antibodies), with IC90 values ranging from 0.0007 g/ml to
0.03 g/ml (5 to 200 pM) (Table 1 and Fig. 1). These anti-
bodies did not neutralize infection of fibroblasts but potently
neutralized infection of HUVEC and Mo-DC with IC50 values
ranging from 0.00024 to 0.019 g/ml (Table 2).
Taken together, the above results delineate two broad groups
of HCMV-neutralizing antibodies with distinct specificities. A
first group of antibodies have a broad cell target specificity
since they neutralize infection of all target cells tested in the
nanomolar range. A second group of antibodies does not in-
hibit infection of fibroblasts but neutralizes with an extraordi-
narily high potency (in the picomolar range) infection of epi-
thelial, endothelial, and myeloid cells.
Recognition of the gH/gL/UL128-UL131A complex by HCMV-
neutralizing antibodies. Consistent with recognition of struc-
tural viral antigens and not host cell determinants, the isolated
antibodies stained punctate structures in the perinuclear re-
gion of fibroblasts at late stages of infection (not shown). Given
the essential role of UL128, UL130, and UL131A gene prod-
ucts in HCMV endothelial cell tropism, we hypothesized that
group 2 antibodies, which neutralized infection of epithelial
and endothelial cells but not of fibroblasts, would bind to the
product of one of these genes. Staining of MRC-9 cells that
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had been infected with either VR1814 or a mutant virus car-
rying a deletion of the UL132-128 region (RVFIXUL132-
128) (21) indicated that 1F11, 2F4, and 6G4 (but not group 1
antibody 5F1) indeed recognize a product that requires an
intact UL132-128 gene locus (data not shown).
To map antibody specificities, HCMV genes UL128, UL130,
and UL131A were overexpressed in HEK293T cells and
transfected cells were stained with the monoclonal antibod-
ies. Surprisingly, with the exception of antibody 15D8, which
stained UL128-transfected cells, all the other antibodies did
not stain single-gene transfectants (Fig. 2 and data not
shown). We therefore considered the possibility that the
antibodies might recognize epitopes that require coexpres-
sion of more than one gene product. Indeed, eight group 2
antibodies (1F11, 2F4, 4I22, 4N10, 5A2, 8L13, 10F7, and
10P3) stained cells coexpressing UL130 and UL131A, while
seven group 2 antibodies (2C12, 6G4, 7B13, 7I13, 8C15,
8J16, and 9I6) stained cells coexpressing UL128, UL130,
and UL131A, and finally one antibody (8I21) stained cells
transfected with UL128 and UL130 as well as with gH and
gL. All these antibodies also stained HEK293T cells trans-
fected with all genes forming the gH/gL/UL128-131A com-
plex (Fig. 2 and data not shown).
These results demonstrate that human monoclonal antibod-
ies that potently neutralize infection of epithelial, endothelial,
and myeloid cells bind to the gH/gL/UL128-131A complex.
With the exception of antibody 15D8, which binds to UL128,
all antibodies bind epitopes that require coexpression of two or
more HCMV proteins.
Antigenic sites in the gH/gL/UL128-131A complex recog-
nized by group 2 neutralizing antibodies. To map the antigenic
sites of the gH/gL/UL128-131A complex, we performed cross-
competition experiments. HEK293T cells transfected with the
five HCMV genes were preincubated with a 20-fold excess of
unlabeled competitor antibodies followed by addition of a bi-
otin-labeled antibody. By this means seven distinct antigenic
sites could be identified (Table 3). Site 1 is present in UL128
and is defined by antibody 15D8. Sites 2 to 4 are formed by the
combination of UL130 and UL131A and are defined by the
antibodies 1F11, 2F4, 4I22, and 10F7 (site 2); 4N10 and 5A2
(site 3); and 10P3 (site 4), respectively. Sites 5 and 6 are
formed by the combination of UL128, UL130, and UL131A
and are defined by antibodies 2C12, 6G4, 8C15, 8J16, and 9I6
(site 5) and 7I13 (site 6), respectively. Finally, site 7 is formed
by the combination of gH, gL, UL128, and UL130 and is
defined by antibody 8I21. Antibodies defining site 7 and site 3
partially competed with each other (Table 3), suggesting that
these sites may be close in the structure of the gH/gL/UL128-
131A complex.
The above results delineate seven distinct antigenic sites in
the gH/gL/UL128-131A complex and suggest that there might
be a hierarchy of immunodominance among these sites, with
UL130/131A being a major target of neutralizing antibodies.
Interestingly, when we performed a primary screening of B-cell
culture supernatants using staining of HEK293T cells trans-
fected with UL130/131A, all binding antibodies were found
to be also neutralizing. In contrast, when the same screening
strategy was performed with gB or gH transfectants, several
binding antibodies that lacked neutralizing activity were iso-
lated (not shown).
Taken together, these findings indicate that neutralizing
antibodies produced in humans during the course of a nat-
ural infection can be used as tools to identify relevant anti-
genic regions in a complex human pathogen such as HCMV.
Specificity of group 1 antibodies that neutralize infection of
epithelial cells and fibroblasts. Next we determined the anti-
genic specificity of group 1 antibodies that neutralized infec-
tion of all target cells tested, including fibroblasts. Staining of
HEK293T-transfected cells revealed that 3G16, 11B12, and
13H11 bind to gH, whereas 2B11, 4H9, 5F1, 6B4, 7H3, and
10C6 bind to gB. One antibody, 6L3, stained cells cotrans-
fected with gM and gN. Cross-competition experiments indi-
cated the presence of at least three distinct neutralizing anti-
genic sites on gB and two on gH (Tables 4 and 5 and data not
shown). Antibody 6B4 reacted by enzyme-linked immunosor-
bent assay (ELISA) with gB 69-78 peptide (50% effective con-
centration [EC50] of 0.044 g/ml) (data not shown), which was
previously defined as a target of human neutralizing antibodies
(30, 31). Of note, gH-specific antibodies did not compete with
antibody 8I21, which binds to gH/gL/UL128/130, nor with any
TABLE 1. HCMV-neutralizing antibodies isolated from
immune donorsa
Groupb and MAb Donor Ig isotype
IC90 (g/ml) for
cell line:
MRC-9 ARPE-19
1
3G16 A IgG3,  1 0.3
11B12 D IgG1,  3.5 1.2
13H11 B IgG1,  1.12 0.4
2B11 A IgG3,  0.75 0.2
4H9 A IgG3,  10 0.4
5F1 A IgG3,  0.5 0.1
6B4 A IgG1,  1 0.15
7H3 A IgG1,  3 0.6
10C6 A IgG3,  0.75 0.2
6L3 A IgG1,  30 10
2
15D8 B IgG3,  NNc 0.008
1F11 A IgG1,  NN 0.001
2F4 A IgG1,  NN 0.001
4I22 A IgG1,  NN 0.0015
4N10 C IgG1,  NN 0.02
5A2 B IgG3,  NN 0.023
8L13 A IgG1,  NN 0.001
10F7 D IgG1,  NN 0.002
10P3 A IgG3,  NN 0.0025
2C12 D IgG1,  NN 0.006
6G4 A IgG1,  NN 0.0045
7B13 D IgG1,  NN 0.003
7I13 D IgG1,  NN 0.008
8J16 D IgG1,  NN 0.0008
8C15 D IgG1,  NN 0.0025
9I6 A IgG1,  NN 0.0007
8I21 A IgG1,  NN 0.03
a HCMV VR1814 was incubated with different dilutions of the indicated
human MAbs for 2 h, and the mixture was added to monolayers of fibroblasts
(MRC-9) or epithelial cells (ARPE-19). Infected cells were detected by staining
with a mouse anti-pp72 MAb after 48 h. The IC90 values correspond to the MAb
concentration that leads to 90% reduction of infected cells.
b Group 1, MAbs neutralizing infection of fibroblasts and epithelial cells;
group 2, MAbs neutralizing infection of epithelial cells but not fibroblasts.
c NN, nonneutralizing at the highest concentration tested (10 g/ml).
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of the other antibodies directed against the gH/gL/UL128-
131A complex (data not shown).
In summary, targeting any of the glycoprotein complexes of
the envelope is sufficient to completely block infection of en-
dothelial and epithelial cells, indicating that besides UL128/
UL130/UL131A other proteins are also essential for infection
of such cell types.
Breadth of neutralizing activity of group 1 and group 2
human monoclonal antibodies. In contrast to other HCMV
genes, UL128, UL130, and UL131A genes are relatively con-
served among HCMV isolates and may therefore represent an
attractive target for vaccination (2). We therefore investigated
whether antibodies neutralizing the VR1814 isolate might be
capable of neutralizing different HCMV strains. The three
antibodies tested (1F11, 2F4, and 6G4) neutralized to the same
extent infection of HUVEC by the reference virus VR1814 and
by the three additional isolates VR6952, VR3480B1 (ganciclo-
vir resistant), and VR4760 (ganciclovir and foscarnet resistant)
(Table 2) (3, 42, 50).
UL128 is the most conserved gene of the UL132-128 locus,
and we found that it is a target of antibodies with potent
neutralizing activity, such as 15D8. However, sequences de-
rived from several clinical isolates revealed the existence of
10 variants with one or more mutations compared to the
VR1814 sequence (2). We therefore investigated whether
the binding of 15D8 would be affected by any of these
mutations. Published amino acid sequences of variants of
UL128 from clinical isolates (2) and laboratory strains
(Towne, TB40/E, AD169, Merlin, and Toledo) were aligned,
and a gene encoding a protein that includes all amino acid
substitutions described as well as an additional mutation
that we found to be generated at very high frequency in vitro
upon PCR amplification (F33V) was synthesized. HEK293T
cells were transfected with the original UL128 gene from
VR1814 or with the pan-mutated gene and stained with
serial dilutions of 15D8. As shown in Fig. 3, the original and
the pan-mutated UL128 protein were recognized by 15D8
with comparable efficiencies (saturated staining at 0.2
M M
FIG. 1. Microneutralization assays on human fibroblasts and epithelial cells reveal two types of HCMV human monoclonal neutralizing
antibodies. Human IgG memory B cells from HCMV-immune donors were immortalized with EBV and B-cell clones producing MAbs capable
of neutralizing HCMV infection of fibroblasts (MRC-9) or retinal epithelial cells (ARPE-19) were isolated. (A) An appropriate dilution of the
HCMV clinical isolate VR1814 was incubated for 2 h in the absence or presence of MAbs at 1 g/ml before addition to target cells. Infected cells
were detected by staining with anti-pp72 mouse MAb 48 h after infection. Representative staining of antibodies belonging to the two groups is
shown (one field of acquisition of nine fields analyzed). (B) Microneutralization assays with different concentrations of three representative
antibodies performed as for panel A. The mean of measurements of duplicate wells 	 standard error from one experiment out of three performed
was plotted, and nonlinear sigmoidal dose-response fit curves for each MAb were calculated. IC90 values for all antibodies and target cells are
shown in Table 1.
TABLE 2. Neutralization of HCMV clinical isolates infecting
primary cellsa
Group
and
MAb
IC50 (g/ml) for cell type and clinical isolate
HUVEC Mo-DC
(VR1814)
MSC
(VR1814)VR1814 VR6952b VR3480B1c VR4760c
1
5F1 0.21 0.21 0.21 0.21 0.05 0.3
6B4 NDd ND ND ND 0.11 2
7H3 ND ND ND ND 0.06 2
10C6 0.19 0.19 0.19 0.19 0.02 0.3
2
1F11 0.0034 0.0034 0.0034 0.0034 0.0003 
17
2F4 0.0033 0.0033 0.0033 0.0033 0.00024 
12
6G4 0.019 0.019 0.019 0.019 0.00024 
8.5
a Neutralization assays were performed as for Table 1 using HCMV clinical
isolates and primary cells.
b From urine of a congenitally infected baby.
c From blood of an AIDS patient.
d ND, not done.
1008 MACAGNO ET AL. J. VIROL.
 by M
arcus Thelen on M
arch 30, 2010 
jvi.asm.org
D
ow
nloaded from
 
g/ml [data not shown]). These findings indicate that 15D8
recognizes a highly conserved epitope in the UL128-en-
coded protein.
DISCUSSION
By combining an efficient method of memory B-cell immor-
talization with a screening for neutralization of HCMV infec-
tion of different target cells, we have been able to isolate a
panel of HCMV-neutralizing human antibodies representative
of those elicited during natural infection. The antibodies fall
into two main groups. A first group includes 10 antibodies that
bind to previously identified targets, including gH, gB, and
gM/gN. These antibodies neutralize in the nanomolar range
infection of all cell types tested, including fibroblasts. In con-
trast, a second group includes 17 antibodies that bind to several
novel epitopes of the gH/gL/UL128-131A complex. They neu-
tralize at picomolar concentrations infection of epithelial, en-
dothelial, and myeloid cells but not infection of fibroblasts.
These findings illustrate the advantages of interrogating the
human immune response to a human pathogen using viral
neutralization as a primary screening.
Genetic and biochemical studies demonstrated the existence
M
M
FIG. 2. Staining of HEK293T cells expressing HCMV antigens determines the antigenic specificity of human MAbs. HCMV genes UL128,
UL130, UL131A, gH, and gL were cloned and transfected in HEK293T cells in different combinations. The cells were fixed, permeabilized, and
stained with the neutralizing antibodies. Ectopic expression of antigens was confirmed by reactivity with mouse antibodies (not shown). Shown are
representative profiles for MAbs 15D8, 1F11, 2C12, and 8I21.
TABLE 3. Antigenic sites on the gH/gL/UL128-131A complex recognized by group 2 human HCMV-neutralizing antibodies
Unlabeled
competitora MAb specificity
Inhibition of binding (%) of biotinylated MAbs to cells expressing the gH/gL/UL128-131A complexb Assigned
antigenic
sitec15D8 1F11 2F4 4I22 10F7 4N10 5A2 2C12 6G4 8C15 9I6 8J16 8I21
15D8 UL128 100 0 0 0 0 0 0 0 0 NDd ND ND 0 1
1F11 UL130/131A 0 100 100 100 100 0 0 0 0 ND ND ND 0 2
2F4 UL130/131A ND 100 100 100 100 0 0 0 0 ND 0 ND 0 2
4I22 UL130/131A ND 100 100 100 100 0 0 0 ND ND ND 0 0 2
8L13 UL130/131A ND 100 ND ND 100 ND ND ND ND ND ND ND ND 2
10F7 UL130/131A 0 100 100 100 100 0 0 0 0 ND ND ND 0 2
4N10 UL130/131A 0 0 0 0 0 100 100 0 0 ND ND ND 90 3
5A2 UL130/131A ND 0 50 0 0 100 100 0 0 ND 0 ND 92 3
10P3 UL130/131A 0 0 0 0 ND 0 ND 0 0 ND ND ND 0 4
2C12 UL128/130/131A 0 0 0 0 0 0 0 100 100 100 100 100 0 5
6G4 UL128/130/131A 0 0 0 0 0 0 0 100 100 100 100 100 0 5
8C15 UL128/130/131A ND ND ND 0 ND ND ND 100 100 100 100 100 0 5
9I6 UL128/130/131A ND 0 0 0 ND ND ND 100 100 100 100 100 0 5
7B13 UL128/130/131A ND ND ND ND ND ND ND 100 100 100 100 100 0 5
8J16 UL128/130/131A ND 0 0 0 ND ND ND 100 100 100 70 100 0 5
7I13 UL128/130/131A ND 0 ND ND ND ND ND 0 0 0 0 0 0 6
8I21 gH/gL/UL128/130 0 0 0 0 ND 90 95 0 0 ND 0 ND 100 7
a HEK293T cells transfected with gH/gL/UL128-131A genes were permeabilized and incubated with a 20-fold excess of unlabeled competitor MAb followed by
staining with biotinylated MAbs. Antibodies 10P3 and 7I13 were tested at 100-fold excess. Specificity of the MAb was assigned based on the minimum requirements
for positive staining of HEK293T cells transfected with HCMV genes in different combinations (not shown).
b Percent inhibition for each antibody combination was calculated as follows: 100  (% transfected cells stained in the presence of competitor/% transfected cells
in the absence of competitor)  100.
c Antigenic sites are assigned on the basis of cross-competition profiles.
d ND, not done.
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of a molecular complex formed by gH, gL, and products of the
UL131A-128 locus which is required for HCMV infection of
endothelial, epithelial, and myeloid cells (1, 18, 21, 36, 62, 63).
This complex was expected to be the target of neutralizing
antibodies, but attempts to produce neutralizing antibodies by
immunizing animals with single proteins of the complex have
met with only limited success. Here we report for the first time
that neutralizing antibodies that bind to UL128, UL130, and
UL131A are elicited during natural infection. Additionally, we
show that such antibodies have an extraordinarily high potency
in neutralizing HCMV infection in vitro. For instance, anti-
bodies 1F11, 2F4, and 6G4 show IC50 values on primary cells
(HUVEC and dendritic cells) as low as 0.0003 g/ml (2 pM).
Recent studies have shown that HCMV-seropositive donors
have titers of antibodies that neutralize infection of endothelial
and epithelial cells that are much higher than the titers of
antibodies neutralizing infection of fibroblasts (10, 20). In light
of our findings, such high titers appear to be due to the potency
rather than the amount of antibodies directed against the gH/
gL/UL128-131A complex. Although we have no explanation
for the extraordinary potency of these antibodies, we can spec-
ulate that this may be due to a combination of high affinity and
high accessibility to target epitopes on infectious viral particles.
The complexity of the antigens that bind such antibodies did
not permit us to make affinity measurements. According to the
occupancy model, viral neutralization is mediated by steric
hindrance of the virus surface by antibody coating (35). In line
with this notion, a possible explanation of the significant dif-
ference in potency between the two groups of antibodies might
come from the relative abundance of the target antigens. It is
possible that the gH/gL/UL128-131A complex is present exclu-
sively on infectious virus, while other glycoproteins such as
gB or gH may be present also on defective viral particles or on
cellular debris. Antibodies specific for such target antigens
could therefore bind to nonfunctional proteins and not be
available for neutralization (38).
Another peculiar feature of these monoclonal antibodies
is that they recognize antigenic sites that require coexpression
of two or more HCMV genes. It remains to be established
whether the antibodies recognize a quaternary structure made
by juxtaposed proteins or a conformational epitope within one
protein that requires pairing with additional proteins in order
to be properly displayed. Using cross-competition experiments,
we were able to assign each antibody to one of seven distinct
sites, thus providing a preliminary antigenic map of the gH/gL/
UL128-131A complex (Fig. 4). Notably, several antibodies iso-
lated from different donors recognized three antigenic sites
formed by the combination of UL130 and UL131A, suggesting
that epitopes within these two proteins are immunodominant.
It is interesting that all the antibodies isolated against the
UL128/UL130/UL131A complex display neutralizing activity
and that we were not able to isolate from immune donors
antibodies that would bind this complex but fail to neutralize.
These findings suggest that the proteins encoded by the
UL131A-128 locus are presented to the immune system as
tight complexes (rather than as single proteins) that are capa-
ble of eliciting protective immunity (47, 63). This may also
explain the poor neutralizing capacity of antibodies raised by
immunizing animals with single recombinant UL128, UL130,
or UL131A protein (1, 20, 63).
It is generally assumed that infection of epithelial cells con-
tributes to interhost transmission and viral spread, while infec-
tion of fibroblasts and smooth muscle cells allows efficient viral
replication. In this context, the interplay between endothelial
cells and leukocytes represents the pathogenetic basis for all
clinical syndromes originating during disseminated HCMV in-
fection (37, 43, 53). In line with the notion that cell-to-cell
spreading requires UL131A-128 gene products (25), prelimi-
nary experiments indicate that, similarly to mouse antibodies
to UL128 or UL130 (20), antibodies 1F11 and 2F4 block trans-
fer of HCMV from HUVEC or human embryonic lung fibro-
blasts to leukocytes (not shown). Therefore, the ability to neu-
tralize viral entry into endothelial and epithelial cells is
expected to be critical for protection from viral pathogenicity.
Sequence variation among different strains is a common
issue in vaccine development against viruses, including HCMV,
for which unusually high variation of a subset of genes has been
described elsewhere (11). Interestingly, in contrast to genes
such as gO that show only 45% identical amino acid sequences
in isolates from different sources (40), the UL131A-128 gene
locus appears to be more conserved, with 91% amino acid
identity of the gene products (2). We have been able to dem-
onstrate that antibody 15D8 is directed against a highly con-
served epitope within UL128 and that antibodies 1F11, 2F4,
TABLE 5. Antigenic sites of group 1 human HCMV-neutralizing
antibodies specific for gBa
Unlabeled
competitor
Inhibition of binding (%) of biotinylated MAbb: Assigned
antigenic
sitec2B11 4H9 5F1 10C6 6B4 7H3
6B4 0 5 0 0 100 6 1
7H3 0 0 0 0 0 100 2
2B11 100 100 100 100 0 0 3
4H9 100 100 100 100 0 0 3
5F1 100 100 100 100 0 0 3
10C6 100 100 100 100 0 3 3
a HEK293T cells transfected with the gB gene were permeabilized and incu-
bated with a 20-fold excess of unlabeled competitor MAb followed by staining
with biotinylated MAbs. The specificity of the MAbs indicates their binding to
gB-expressing cells.
b Percent inhibition for each antibody combination was calculated as follows:
100  (% transfected cells stained in the presence of competitor/% transfected
cells in the absence of competitor)  100.
c Antigenic sites are assigned on the basis of cross-competition profiles.
TABLE 4. Antigenic sites of group 1 human HCMV-neutralizing
antibodies specific for gHa
Unlabeled
competitor
Inhibition of binding (%) of
biotinylated MAbb: Assigned
antigenic sitec
3G16 11B12 13H11
3G16 100 15 14 1
11B12 6 100 100 2
13H11 0 100 100 2
a HEK293T cells transfected with the gH gene were permeabilized and incu-
bated with a 20-fold excess of unlabeled competitor MAb followed by staining
with biotinylated MAbs. The specificity of the MAbs indicates their binding to
gH-expressing cells.
b Percent inhibition for each antibody combination was calculated as follows:
100  (% transfected cells stained in the presence of competitor/% transfected
cells in the absence of competitor)  100.
c Antigenic sites are assigned on the basis of cross-competition profiles.
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and 6G4 are capable of neutralizing with similar efficiencies
different HCMV clinical isolates. This makes monoclonal an-
tibodies specific for conserved epitopes formed by UL128,
UL130, or UL131A promising candidates for passive immuno-
therapy and the corresponding sites on the complexes appeal-
ing candidates for a vaccine capable of inducing potent and
broadly reactive neutralizing antibodies.
In conclusion, by combining the human memory B-cell im-
mortalization method (59) with the antibody-driven target dis-
covery approach (7), we have been able to exploit the strength
of the human antibody response to isolate broadly reactive and
potent neutralizing antibodies against HCMV and to identify
novel antigenic sites on the gH/gL/UL128-131A complex. The
high potency of natural antibodies binding the UL128/130/
131A complex and the large number of different epitopes dis-
played on these proteins suggest a novel subunit vaccine alter-
native to gB (10). These results illustrate the feasibility of a
general approach to study human pathogens and support the
value of the “analytic vaccinology” approach in the process of
vaccine design (7, 27). Indeed, if the goal of vaccination is to
mimic natural immunity by providing native antigen, prepara-
tions of vaccine candidates may be examined for their reactiv-
ity with neutralizing antibodies, and the response to vaccina-
tion may be monitored for elicitation of antibodies with similar
binding profiles.
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